



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

BRINGHURST *et al.*

Appl. No. 09/696,982

Filed: October 27 2000

For: Screening Assays for G Protein  
Coupled Receptor Agonists and  
Antagonists

Confirmation No. 1728

Art Unit: 1646

Examiner: Ulm, John D.

Atty. Docket: 0609.4430001/LBB/JAH

RECEIVED  
MAY 07 2003  
GROUP 1700

#16

MQJ

5/13/03

**First Supplemental Information Disclosure Statement**

**RECEIVED**

MAY 08 2003

TECH CENTER 1600/2900

Director of the United States  
Patent and Trademark Office  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on the First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed February 1, 2001 in connection with the above captioned application. A copy of each of these documents is provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates

should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that an exhaustive search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

The First Supplemental Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

In accordance with 37 C.F.R. § 1.97(c), fee payment under 37 C.F.R. § 1.17(p) is provided. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Lawrence B. Bugaisky  
Attorney for Applicants  
Registration No. 35,086

Date: May 5, 2003

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

::ODMA\MHODMA\SKGF\_DC1;129679;1  
SKGF Rev. 12/18/02 mac; 4/18/03 svb